製药和生物技术资产收购交易：2019-2025

本报告研究了製药和生物技术行业的资产购买交易趋势，深入了解和分析了公司如何以及为何进行业务、产品、技术和特许权使用费的资产购买交易。

此报告提供双方宣布的资产购买交易的付款条款。这些数据可以为付款条款和其他贸易条款提供有价值的见解。

本报告聚焦在四种主要可供购买的资产类型：

• 商业资产
• 产品资产
• 特许权资产
• 技术资产

主要优点：

本报告提供以下主要优势：

• 了解 2019 年及以后的交易趋势
• 您可以查看资产购买交易
• 基准分析 - 确定交易的市场价值
• 财务 - 查看标题、预付、里程碑和版税率
• 按公司（AZ）、治疗领域和技术类型浏览交易目录
• 您可以查看主要交易金额
• 看看谁是最活跃的交易者
• 确定每笔交易的资产和条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议的商业条款是否适合您的合作伙伴
• 节省数百小时的研究时间

研究范围：

• 生命科学产业资产收购交易趋势
• 资产收购交易结构概述
• 涵盖製药、生物技术、医疗设备和诊断领域的资产购买交易记录目录
• 重大资产购买交易
• 最活跃的资产收购交易者
• 主要资产购买合作伙伴讯息

目录

摘要整理

第1章 简介

第2章 资产购买交易趋势

• 购买了的资产的种类
• 2019年以后的资产购买交易趋势
  • 资产购买交易趋势:各年度
  • 资产购买交易:各开发阶段
  • 资产购买交易:各产业部门
  • 资产购买交易:各治疗领域
  • 资产购买交易:各技术类型
  • 资产购买交易:不过活跃的企业
• 签订资产购买联盟契约的理由
  • 事业资产
  • 产品资产
  • 忠诚度(权利金)资产
  • 技术资产
• 资产购买交易的未来

第3章 资产购买交易结构:概要

• 资产购买交易结构

第4章 主要资产购买交易

• 前几名资产购买交易:各金额

第5章 25 家最活跃的资产收购交易商

• 25 家最活跃的资产收购交易商

第六章 资产购买交易及合约目录

• 2019 年至 2025 年的合约与资产购买交易
• 贸易目录
• 交易目录 - 资产购买交易：按公司 (AZ)
• 交易目录 - 按治疗领域划分的资产购买交易
• 交易目录 - 按技术类型划分的资产收购交易
• 关于Biopharma Research Ltd
• 目前联盟
• 目前契约
• Current Partnering 的最新报告标题

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of asset purchase deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
• Chapter 3 provides an overview of the structure of asset purchase deals.
• Chapter 4 provides a review of the leading asset purchase deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
• Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
• The deal directory includes a comprehensive listing of all asset purchase deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
• The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2019.
• In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse asset purchase deals
• Benchmark analysis - identify market value of transactions
• Financials - headline, upfront, milestone, royalty rates
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Asset Purchase Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals and Biotechnology includes:

• Trends in asset purchase dealmaking in the life sciences industry
• Overview of asset purchase deal structure
• Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
• The leading asset purchase deals by value
• Most active asset purchase dealmakers
• The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.
• Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2019
  • 2.3.1. Asset purchase dealmaking by year, 2019-2025
  • 2.3.2. Asset purchase dealmaking by phase of development, 2019-2025
  • 2.3.3. Asset purchase dealmaking by industry sector, 2019-2025
  • 2.3.4. Asset purchase dealmaking by therapy area, 2019-2025
  • 2.3.5. Asset purchase dealmaking by technology type, 2019-2025
  • 2.3.6. Asset purchase dealmaking by most active company, 2019-2025
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts 2019-2025
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements, 2019-2025
• Figure 3: Asset purchase deals signed at each phase of development, 2019-2025
• Figure 4: Asset purchase deals by industry sector, 2019-2025
• Figure 5: Asset purchase deals by therapy area, 2019-2025
• Figure 6: Asset purchase deals by technology type, 2019-2025
• Figure 7: Top 25 most active asset purchase dealmakers, 2019-2025
• Figure 8: Top asset purchase deals by value, 2019-2025
• Figure 9: Most active asset purchase dealmakers, 2019-2025